Antifungal susceptibility of emerging yeast pathogens

被引:31
作者
García-Martos, P [1 ]
Domínguez, I [1 ]
Marín, P [1 ]
García-Agudo, R [1 ]
Mira, SAYJ [1 ]
机构
[1] Hosp Univ Puerta Mar, Cadiz, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2001年 / 19卷 / 06期
关键词
yeasts; antifungal agents; Candida; fluconazole;
D O I
10.1016/S0213-005X(01)72630-4
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BACKGROUND. To study the antifungal susceptibility of emerging yeast pathogens to know their possible resistance under the need of applying a treatment. MATERIAL AND METHODS. We investigated the in vitro susceptibility of 69 yeast strains isolates of clinical samples, belonging to 24 different species, to amphotericin B, fluconazole, itraconazole, ketoconazole and 5-fluorocytosine. RESULTS. Only 9 species showed susceptibility to all antifungal agents: Candida famata, C. guillermondii, C. holmii, C. kefyr, C. pelliculosa, C. rugosa, C. utilis, C. zeylanoides y Trichosporon cutaneum; the rest of them presented resistance to some antifungal agent. C. haemulonii; Pichia farinosa and Trichosporon mucoides were resistant to amphotericin B; C. haemulonii, C. inconspicua, C. lusitaniae, C. norvegensis, C. pintolepesii, C. valida, P. ohmeri, Rhodotorula glutinis, R. minuta, R. mucilaginosa and Saccharomyces cerevisiae were resistant to azoles; Blastoschizomyces capitatus and C. lipolytica were resistant to 5-fluorocytosine. CONCLUSIONS. The resistance of emerging yeast pathogens to amphotericin B and 5-fluorocytosine is low, while resistance to azoles is significative, especially to fluconazole (36%). Many of this yeasts present problems of intrinsic resistance. In yeast infections, the correct identification of species and the study of the in vitro susceptibility is important in order to choose the most adequate antifungal treatment.
引用
收藏
页码:249 / 256
页数:10
相关论文
共 109 条
[1]   Infectious crystalline keratopathy caused by Candida guilliermondii [J].
Ainbinder, DJ ;
Parmley, VC ;
Mader, TH ;
Nelson, ML .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 125 (05) :723-725
[2]   CATHETER-ASSOCIATED CANDIDA-UTILIS FUNGEMIA IN A PATIENT WITH ACQUIRED IMMUNODEFICIENCY SYNDROME - SPECIES VERIFICATION WITH A MOLECULAR PROBE [J].
ALSINA, A ;
MASON, M ;
UPHOFF, RA ;
RIGGSBY, WS ;
BECKER, JM ;
MURPHY, D .
JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (04) :621-624
[3]  
AREVALO P, 1992, REV IBEROAM MICOL, V9, P94
[4]   Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients [J].
Arikan, S ;
Gur, D ;
Akova, M .
MYCOSES, 1997, 40 (7-8) :291-296
[5]  
ARISOY ES, 1993, PEDIATR INFECT DIS J, V12, P961, DOI 10.1097/00006454-199311000-00017
[6]   Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy [J].
Arzeni, D ;
DelPoeta, M ;
Simonetti, O ;
Offidani, AM ;
Lamura, L ;
Balducci, M ;
Cester, N ;
Giacometti, A ;
Scalise, G .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 1997, 13 (04) :447-450
[7]  
AUCOTT JN, 1990, REV INFECT DIS, V12, P406
[8]   Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus [J].
Baily, GG ;
Moore, CB ;
Essayag, SM ;
deWit, S ;
Burnie, JP ;
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :161-163
[9]   CANDIDA-LUSITANIAE - A NEW OPPORTUNISTIC PATHOGEN OF THE URINARY-TRACT [J].
BAKER, JG ;
NADLER, HL ;
FORGACS, P ;
KURTZ, SR .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1984, 2 (02) :145-149
[10]   IN-VITRO ACTIVITY OF ITRACONAZOLE AGAINST FLUCONAZOLE-SUSCEPTIBLE AND FLUCONAZOLE-RESISTANT CANDIDA-ALBICANS ISOLATES FROM ORAL CAVITIES OF PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS [J].
BARCHIESI, F ;
COLOMBO, AL ;
MCGOUGH, DA ;
FOTHERGILL, AW ;
RINALDI, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (07) :1530-1533